Clinical trial recruitment and retention remain challenging in the quest to bring innovative therapies to all patients in need. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation, particularly among minority groups. The Oncology Pharmacist (TOP) is dedicated to providing comprehensive information aimed at eliminating health disparities and improving access to therapies for people from all populations, including racial and ethnic minorities; people with limited access to healthcare due to lack of financial resources; and people living in rural communities.
This feature in TOP aims to provide ongoing lists of US-based phase 2 or 3 clinical trials that are actively recruiting. This issue is focused on testicular cancer, the April cancer awareness month. Healthcare practitioners may use this listing in discussions with their patients to encourage enrollment. As NCCN has stated, “The best management of any cancer patient is in a clinical trial.”
These clinical trial listings can be found at www.ClinicalTrials.gov.
- A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases (RPLND-Seminoma)
- ClinicalTrials.gov identifier: NCT06932458
- Sponsor: Western University, Canada
- Interventions: Retroperitoneal lymph node dissection (RPLND), open bilateral nerve-sparing RPLND
- A Single-arm, Phase II Clinical Trial of Aspirin to Prevent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy (ASPIRE)
- ClinicalTrials.gov identifier: NCT06866964
- Sponsor: Wake Forest University Health Sciences
- Collaborator: Atrium Health Wake Forest Baptist, Landon Brown, MD
- Interventions: cisplatin-based chemotherapy and low-dose aspirin
- Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
- ClinicalTrials.gov identifier: NCT06041503
- Sponsor: National Cancer Institute, Andrea B Apolo, MD
- Interventions: enfortumab vedotin vs pembrolizumab plus enfortumab vedotin
- Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
- ClinicalTrials.gov identifier: NCT03067181
- Sponsor: Children’s Oncology Group, A. L Frazier
- Collaborator: National Cancer Institute
- Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT)
- ClinicalTrials.gov identifier: NCT06814496
- Sponsor University of Arizona, Charles Hsu, MD; Ricklie Julian, MD
- Collaborator: Amgen
- Interventions: tarlatamab; tarlatamab plus concurrent radiation therapy; tarlatamab plus sequential radiation therapy
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- ClinicalTrials.gov identifier: NCT03959085
- Sponsor: Children's Oncology Group, Jennifer L McNeer
- Collaborator: National Cancer Institute
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- ClinicalTrials.gov identifier: NCT03866382
- Sponsor: National Cancer Institute
- Collaborator: Alliance for Clinical Trials in Oncology, Andrea B Apolo
- At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
- ClinicalTrials.gov identifier: NCT05969860
- Sponsor: Mayo Clinic, Roxana S. Dronca, MD